Cognitive Benefits of Aerobic Exercise Across the Age Span

Completed · Not applicable

Conditions studied: Cognitive Function

In brief

The purpose of this study is to test the hypothesis that aerobic exercise leads improved cognitive function accompanied by increases in gray matter density and changes in functional magnetic resonance imaging (fMRI) patterns of task-related activation.

Key facts

Study ID

NCT01179958

Run by

New York State Psychiatric Institute

People needed

305

Starts

2010-08-01

Expected to finish

2016-06-29

Last updated by the study team

2018-08-17

Who can join

Age: 20 and older, up to 68. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 20-68
• English-speaking
• strongly right-handed
• BMI < 35
• Pre-menopausal (women only): no oral contraceptive use Post-menopausal: no estrogen replacement therapy
• sedentary: VO2 max < 41 and 31.6 ml/kg/min for men age 20-40 and 50-68 and < 35.2 and 26.6 ml/kg/min for women age 20-40 and 50-68 respectively
• participants over age 60 must have ECG within past 3 months

You may not qualify if…

• MRI contraindications (e.g., metallic implants, pacemaker, weight > 350 lbs, waist > 55")
• Hearing impaired/hearing aids, unable to read newspaper at arm's length with corrective lenses
• Objective cognitive impairment
• Ischemic changes, abnormal blood pressure responses, or any significant ectopy during aerobic capacity testing
• Cardiovascular disease
• Uncontrolled high blood pressure (systolic blood pressure ≥ 140 mmHg; or diastolic blood pressure ≥ 90 mmHg on two measures)
• Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or melanoma
• Active hepatic disease (not a history of hepatitis) or primary renal disease requiring dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary hypothalamic failure or insulin dependent diabetes (Type I or II).
• HIV infection
• Pregnant or lactating (participation allowed 3 months after ceasing lactation
• Medications that target CNS (central nervous system, e.g., neuroleptics, anticonvulsants, antidepressants, benzodiazepines) within the last month
• Women: any selective estrogen receptor modulator or aromatase inhibitor Men: androgen ablation/deprivation hormonal therapies
• Any history of psychosis or electroconvulsive therapy
• Psychotic disorder (lifetime)
• Current or recent (within past 12 months) alcohol or substance abuse or dependence. Recent use (past month) of recreational drugs.
• Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis, degenerative diseases, head injury, mental retardation
• Imaged cortical stroke or large subcortical lacunae or infarct or space-occupying lesion (≥ 2 cubic cm). Other findings, e.g., periventricular caps or small white matter hyperintensities, do not result in exclusion
• Diagnosed learning disability, dyslexia
• Current or recent (Past 5 years) Major Depressive Disorder, Bipolar Disorder, or Anxiety Disorder
• Dementia Rating Scale < 135

Where it is running

• Richard Sloan — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.